Martin Holst Lange

We also have the best-in-class oil already on the market in the U.S.

And the Senegimtide offering that is starting phase three will have both a subcutaneous and an oil offering with what we believe will be best-in-class.

We need to follow our philosophy when we do development.

We always want to see differentiated weight loss potential or efficacy potential, but also differentiated safety and tolerability.

We do believe that we will see that when we see Redefine 11.

in terms of weight loss with CachroSemma.

But we also believe that we have that potential for amicretin, which is another version of addressing two biologies.

So you mentioned GLP-1, GIP.

Sanagimtide is GLP-1 plus amlin.

And then we have what we call triagonists, which is basically the next level.

We do, again, believe that that is going to be a very competitive offering individually, but specifically as a portfolio.